Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $225.4 million.

  • Cartesian Therapeutics' Non-Current Assets fell 33.82% to $225.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $893.3 million, marking a year-over-year increase of 179.65%. This contributed to the annual value of $218.4 million for FY2024, which is 190.18% up from last year.
  • Cartesian Therapeutics' Non-Current Assets amounted to $225.4 million in Q3 2025, which was down 33.82% from $225.5 million recorded in Q2 2025.
  • Cartesian Therapeutics' Non-Current Assets' 5-year high stood at $226.2 million during Q3 2024, with a 5-year trough of $13.6 million in Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $17.7 million (2022), whereas its average is $102.5 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 1303.53% in 2023, then surged by 129919.58% in 2024.
  • Cartesian Therapeutics' Non-Current Assets (Quarter) stood at $15.4 million in 2021, then increased by 14.95% to $17.7 million in 2022, then soared by 1107.58% to $214.3 million in 2023, then grew by 1.9% to $218.4 million in 2024, then increased by 3.21% to $225.4 million in 2025.
  • Its last three reported values are $225.4 million in Q3 2025, $225.5 million for Q2 2025, and $224.0 million during Q1 2025.